Stefano Persano

Dr. Stefano Persano

IIT Central Research Labs Genova, Istituto Italiano di Tecnologia (IIT), via Morego 30, 16163 Genova, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
MGMaria L. Guevara
Maria L. Guevara
Francesca PersanoFrancesca Persano
Francesca Persano
Stefano PersanoStefano Persano
Stefano Persano
Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform for the development of novel effective cancer immunotherapies. Advances in non-viral gene delivery technologies, especially the tremendous progress in lipid nanoparticles' manufacturing, have made possible the implementation of mRNA-based antitumor treatments. Several mRNA-based immunotherapies have demonstrated antitumor effect in preclinical and clinical studies, and marked successes have been achieved most notably by its implementation in therapeutic vaccines, cytokines therapies, checkpoint blockade and chimeric antigen receptor (CAR) cell therapy. In this review, we summarize recent advances in the development of lipid nanoparticles for mRNA-based immunotherapies and their applications in cancer treatment. Finally, we also highlight the variety of immunotherapeutic approaches through mRNA delivery and discuss the main factors affecting transfection efficiency and tropism of mRNA-loaded lipid nanoparticles in vivo.

1 May 2017 in Biomaterials
Verified
Journal Article
Closed access
Stefano PersanoStefano Persano
Stefano Persano
MGMaria L. Guevara
Maria L. Guevara
ZLZhaoqi Li
Zhaoqi Li
JMJunhua Mai
Junhua Mai
MFMauro Ferrari
Mauro Ferrari
HSHaifa Shen
Haifa Shen

1 February 2021 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
MGMaria L. Guevara
Maria L. Guevara
Francesca PersanoFrancesca Persano
Francesca Persano
Stefano PersanoStefano Persano
Stefano Persano

11 October 2016 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
AKAyesha Khalid
Ayesha Khalid
Stefano PersanoStefano Persano
Stefano Persano
HSHaifa Shen
Haifa Shen
YZYuliang Zhao
Yuliang Zhao
EBElvin Blanco
Elvin Blanco
JWJoy Wolfram
Joy Wolfram
Introduction: The ultimate goal in the field of drug delivery is to exclusively direct therapeutic agents to pathological tissues in order to increase therapeutic efficacy and eliminate side effects. This goal is challenging due to multiple transport obstacles in the body. Strategies that improve drug transport exploit differences in the characteristics of normal and pathological tissues. Within the field of oncology, these concepts have laid the groundwork for a new discipline termed transport oncophysics. Areas covered: Efforts to improve drug biodistribution have mainly focused on nanocarriers that enable preferential accumulation of drugs in diseased tissues. A less common approach to enhance drug transport involves priming strategies that modulate the biological environment in ways that favor localized drug delivery. This review discusses a variety of priming and nanoparticle design strategies that have been used for drug delivery. Expert opinion: Combinations of priming agents and nanocarriers are likely to yield optimal drug distribution profiles. Although priming strategies have yet to be widely implemented, they represent promising solutions for overcoming biological transport barriers. In fact, such strategies are not restricted to priming the tumor microenvironment but can also be directed toward healthy tissue in order to reduce nanoparticle uptake.

7 August 2019 in ACS Omega
Verified
Journal Article
Open access
MGMaria L. Guevara
Maria L. Guevara
ZJZachary Jilesen
Zachary Jilesen
DSDavid Stojdl
David Stojdl
Stefano PersanoStefano Persano
Stefano Persano
Recently, the use of mRNA-based vaccines for cancer immunotherapy has gained growing attention. Several studies have shown that mRNA delivered in a vectorized format can generate a robust and efficient immune response. In this work, a new lipopolyplex vector (multi-LP), incorporating the immune adjuvant α-galactosylceramide (α-GalCer) and a multivalent cationic lipid, was proposed for the in vivo delivery of mRNA into antigen-presenting cells. We demonstrate that dendritic cells (DCs) can be targeted in vivo by intravenous administration of a α-GalCer-/mRNA-loaded multi-LP vector, without the need for its functionalization with cell-specific antibodies or ligands. The multi-LP nanoparticles loaded with a reporter mRNA efficiently led to high expression of the enhanced green fluorescence protein in DCs both in vitro and in vivo, exhibiting an intrinsic selectivity for DCs. Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor. This study provides the first evidence that a combination of antigen-mRNA and α-GalCer can be used as an effective antitumor vaccine, inducing strong innate and adaptive immune responses.

16 August 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MGMaria L. Guevara
Maria L. Guevara
Stefano PersanoStefano Persano
Stefano Persano
Francesca PersanoFrancesca Persano
Francesca Persano
Cancer vaccines have been widely explored as a key tool for effective cancer immunotherapy. Despite a convincing rationale behind cancer vaccines, extensive past efforts were unsuccessful in mediating significantly relevant anti-tumor activity in clinical studies. One of the major reasons for such poor outcome, among others, is the low immunogenicity of more traditional vaccines, such as peptide-, protein- and DNA- based vaccines. Recently, mRNA emerged as a promising alternative to traditional vaccine strategies due to its high immunogenicity, suitability for large-scale and low-cost production, and superior safety profile. However, the clinical application of mRNA-based anti-cancer vaccines has been limited by their instability and inefficient in vivo delivery. Recent technological advances have now largely overcome these issues and lipid-based vectors have demonstrated encouraging results as mRNA vaccine platforms against several types of cancers. This review intends to provide a detailed overview of lipid-based vectors for the development of therapeutic mRNA-based anti-tumor vaccines.